{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:00:11Z","timestamp":1785276011733,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1038\/s41415-020-1642-3","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T09:04:15Z","timestamp":1592211855000},"page":"886-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature"],"prefix":"10.1038","volume":"228","author":[{"given":"Nupur","family":"Kanwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allauddin","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"1642_CR19561","doi-asserted-by":"crossref","unstructured":"Marx R E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"1642_CR19564","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433-441.","DOI":"10.1016\/j.tripleo.2006.06.004"},{"key":"1642_CR19566","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Dodson T B, Fantasia J et al. American Association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 2014; 72: 1938-1956.","DOI":"10.1016\/j.joms.2014.04.031"},{"key":"1642_CR19568","doi-asserted-by":"crossref","unstructured":"Almazrooa S A, Woo S B. Bisphosphonate and Nonbisphosphonate-Associated Osteonecrosis of the Jaw. J Am Dent Assoc 2009; 140: 864-875.","DOI":"10.14219\/jada.archive.2009.0280"},{"key":"1642_CR19570","doi-asserted-by":"crossref","unstructured":"Russmueller G, Seemann R, Weiss K, Stadler V, Speiss M, Perisanidis C. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep 2016; 6: 31604.","DOI":"10.1038\/srep31604"},{"key":"1642_CR19573","doi-asserted-by":"crossref","unstructured":"Beth-Tasdogan N H, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev 2017; DOI: 10.1002\/14651858.CD012432.pub2.","DOI":"10.1002\/14651858.CD012432.pub2"},{"key":"1642_CR19575","doi-asserted-by":"crossref","unstructured":"Chahine C J, Cheung M S, Head T W, Schwartz S, Glorieux F H, Rauch F. Tooth extraction socket healing in paediatric patients treated with intravenous pamidronate. J Pediatr 2008; 153: 719-720.","DOI":"10.1016\/j.jpeds.2008.05.003"},{"key":"1642_CR19577","doi-asserted-by":"crossref","unstructured":"Cohen N, Cohen-L\u00e9vy J. Healing processes following tooth extraction in orthodontic cases. J Dentofacial Anom Orthod 2014; 17: 304.","DOI":"10.1051\/odfen\/2014006"},{"key":"1642_CR19579","unstructured":"Rucci N. Molecular biology of bone remodelling. Clin Cases Mineral Bone Metab 2008; 5: 49-56."},{"key":"1642_CR19583","doi-asserted-by":"crossref","unstructured":"Farina R, Trombelli L. Wound healing of extraction sockets. Endod Topics 2011; 25: 16-43.","DOI":"10.1111\/etp.12016"},{"key":"1642_CR19585","doi-asserted-by":"crossref","unstructured":"Allen M R. The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. Odontology 2011; 99: 8-17.","DOI":"10.1007\/s10266-010-0153-0"},{"key":"1642_CR19587","doi-asserted-by":"crossref","unstructured":"Lizuka T, Miller S C, Marks Jr S C. Alveolar bone remodeling after tooth extraction in normal and osteopetrotic (ia) rats. J Oral Pathol Med 1992; 21: 150-155.","DOI":"10.1111\/j.1600-0714.1992.tb00092.x"},{"key":"1642_CR19590","doi-asserted-by":"crossref","unstructured":"Siddiqi A, Payne A G, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; DOI: 10.1016\/j.tripleo.2009.04.027.","DOI":"10.1016\/j.tripleo.2009.04.027"},{"key":"1642_CR19592","doi-asserted-by":"crossref","unstructured":"Otto S, Schreyer C, Hafner S et al. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2012; 40: 303-309.","DOI":"10.1016\/j.jcms.2011.05.003"},{"key":"1642_CR19594","doi-asserted-by":"crossref","unstructured":"Otto S, Tr\u00f6ltzsch M, Jambrovic V, Panya S, Probst F, Ristow O. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg 2015; 43: 847-854.","DOI":"10.1016\/j.jcms.2015.03.039"},{"key":"1642_CR19596","doi-asserted-by":"crossref","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.","DOI":"10.1016\/j.joms.2006.10.061"},{"key":"1642_CR19599","doi-asserted-by":"crossref","unstructured":"Hellstein J. Osteochemonecrosis: An Overview. Head Neck Pathol 2014; 8: 482-490.","DOI":"10.1007\/s12105-014-0583-z"},{"key":"1642_CR19601","doi-asserted-by":"crossref","unstructured":"Aghaloo T L, Felsenfeld A L, Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab. J Oral Maxillofac Surg 2010; 68: 959-963.","DOI":"10.1016\/j.joms.2009.10.010"},{"key":"1642_CR19603","doi-asserted-by":"crossref","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27: 356-362.","DOI":"10.1200\/JCO.2009.21.9584"},{"key":"1642_CR19607","doi-asserted-by":"crossref","unstructured":"Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop T S, Brinzaniuc K. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 2013; 5: 1.","DOI":"10.1186\/2045-824X-5-1"},{"key":"1642_CR19609","unstructured":"Tohashi K, Nakabayashi M, Kodani I, Kidani K, Ryoke K. Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents. Yonago Acta Medica 2016; 59: 45-53."},{"key":"1642_CR19611","doi-asserted-by":"crossref","unstructured":"Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prevent Communit Dent 2016; 6: 97-104.","DOI":"10.4103\/2231-0762.178742"},{"key":"1642_CR19613","doi-asserted-by":"crossref","unstructured":"Nisi M, La Ferla F, Karapetsa D, Gennai S, Miccoli M, Baggiani A. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg 2015; 44: 586-591.","DOI":"10.1016\/j.ijom.2015.01.014"},{"key":"1642_CR19616","doi-asserted-by":"crossref","unstructured":"Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg 2015; 43: 290-293.","DOI":"10.1016\/j.jcms.2014.11.014"},{"key":"1642_CR19618","doi-asserted-by":"crossref","unstructured":"Devlin H, Greenwall-Cohen J, Benton J, Goodwin T L, Littlewood A, Horner K. Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis. Br Dent J 2018; 224: 26-31.","DOI":"10.1038\/sj.bdj.2017.1001"},{"key":"1642_CR19620","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Dodson T B, Assael L A, Landesberg R, Marx R E, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009; 67(5 Suppl): 2-12.","DOI":"10.1016\/j.joms.2009.01.009"},{"key":"1642_CR19622","doi-asserted-by":"crossref","unstructured":"Estilo C L, Van Poznak C H, Wiliams T et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008; 13: 911-920.","DOI":"10.1634\/theoncologist.2008-0091"},{"key":"1642_CR19625","doi-asserted-by":"crossref","unstructured":"McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis 2018; 24: 527-536.","DOI":"10.1111\/odi.12708"},{"key":"1642_CR19627","doi-asserted-by":"crossref","unstructured":"Lazarovici T S, Yahalom R, Taicher S et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010; 68: 790-796.","DOI":"10.1016\/j.joms.2009.09.017"},{"key":"1642_CR19630","doi-asserted-by":"crossref","unstructured":"Diniz-Freitas M, Fern\u00e1ndez-Feijoo J, Diz-Dios P, Pousa X, Limeres J. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report. J Clin Periodontol 2018; 45: 570-577.","DOI":"10.1111\/jcpe.12882"},{"key":"1642_CR19633","doi-asserted-by":"crossref","unstructured":"Fleisher K E, Welch G, Kottal S, Craig R G, Saxena D, Glickman R S. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110: 509-516.","DOI":"10.1016\/j.tripleo.2010.04.023"},{"key":"1642_CR19635","doi-asserted-by":"crossref","unstructured":"Marx R E, Cillo Jr J E, Ulloa J J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410.","DOI":"10.1016\/j.joms.2007.08.003"},{"key":"1642_CR19638","doi-asserted-by":"crossref","unstructured":"Moore A, Renton T, Taylor T, Popat S, Popat R, Sivardeen Z. Oral surgery: ARONJ masterclass. Br Dent J 2014; 216: 488-489.","DOI":"10.1038\/sj.bdj.2014.360"},{"key":"1642_CR19640","doi-asserted-by":"crossref","unstructured":"Fliefel R, Tr\u00f6ltzsch M, K\u00fchnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015; 44: 568-585.","DOI":"10.1016\/j.ijom.2015.01.026"},{"key":"1642_CR19642","doi-asserted-by":"crossref","unstructured":"Neer R M, Arnaud C D, Zanchetta J R et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.","DOI":"10.3171\/foc.2001.11.2.8"},{"key":"1642_CR19644","doi-asserted-by":"crossref","unstructured":"Bakr M M, Kelly W L, Brunt A R et al. Single injection of PTH improves osteoclastic parameters of remodeling at a stress fracture site in rats. J Orthop Res 2019; 37: 1172-1182.","DOI":"10.1002\/jor.24262"},{"key":"1642_CR19647","doi-asserted-by":"crossref","unstructured":"Spanou A, Lyritis G P, Chronopoulos E, Tournis S. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review. Oral Diseases 2015; 21: 927-936.","DOI":"10.1111\/odi.12333"},{"key":"1642_CR19649","doi-asserted-by":"crossref","unstructured":"Bagan J, Peydr\u00f3 A, Calvo J, Leopoldo M, Jim\u00e9nez Y, Bagan L. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Oral Diseases 2016; 22: 324-329.","DOI":"10.1111\/odi.12447"},{"key":"1642_CR19652","unstructured":"Vescovi P. Bisphosphonates and osteonecrosis: an open matter. Clin Cases Miner Bone Metab 2012; 9: 142-144."},{"key":"1642_CR19655","doi-asserted-by":"crossref","unstructured":"Rollason V, Laverri\u00e8re A, MacDonald L C I, Walsh T, Tram\u00e8r M R, Vogt-Ferrier N B. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev 2016; DOI: 10.1002\/14651858.CD008455.pub2.","DOI":"10.1002\/14651858.CD008455.pub2"},{"key":"1642_CR19657","doi-asserted-by":"crossref","unstructured":"Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg 2016; 44: 1067-1072.","DOI":"10.1016\/j.jcms.2016.05.004"},{"key":"1642_CR19659","doi-asserted-by":"crossref","unstructured":"Melville J C, Tursun R, Shum J W, Young S, Hanna I A, Marx R E. A technique for the treatment of oral-antral fistulas resulting from medication-related osteonecrosis of the maxilla: the combined buccal fat pad flap and radical sinusotomy. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 122: 287-291.","DOI":"10.1016\/j.oooo.2016.03.015"},{"key":"1642_CR19661","doi-asserted-by":"crossref","unstructured":"Jo\u00e3o B, Blessmann W, Camilotti R S, Ponte M E. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. Lasers Med Sci 2016; 31: 1261-1272.","DOI":"10.1007\/s10103-016-1929-4"},{"key":"1642_CR19665","doi-asserted-by":"crossref","unstructured":"Mester E, Spiry T, Szende B, Tota J G. Effect of laser rays on wound healing. Am J Surg 1971; 122: 532-535.","DOI":"10.1016\/0002-9610(71)90482-X"},{"key":"1642_CR19667","doi-asserted-by":"crossref","unstructured":"Halon A, Donizy P, Dziegala M, Dobrakowski R, Simon K. Tissue laser biostimulation promotes post-extraction neoangiogenesis in HIV-infected patients. Lasers Med Sci 2015; 30: 701-706.","DOI":"10.1007\/s10103-013-1411-5"},{"key":"1642_CR19669","doi-asserted-by":"crossref","unstructured":"Lyttle C V, Paterson H. Denosumab: a case of MRONJ with resolution. Br Dent J 2016; 220: 623-625.","DOI":"10.1038\/sj.bdj.2016.443"},{"key":"1642_CR19671","doi-asserted-by":"crossref","unstructured":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"1642_CR19674","unstructured":"Bedogni A. Position papers in the medical literature: lights and shadows for ONJ treatment. Annali di Stomatologia 2015; 6: 64-66."},{"key":"1642_CR19676","doi-asserted-by":"crossref","unstructured":"Aghaloo T L, Kang B, Sung E C et al. Periodontal Disease and Bisphosphonates Induce Osteonecrosis of the Jaws in the Rat. J Bone Miner Res 2011; 26: 1871-1882.","DOI":"10.1002\/jbmr.379"},{"key":"1642_CR19679","doi-asserted-by":"crossref","unstructured":"Brown J P, Prince R L, Deal C et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009: 24: 153-161.","DOI":"10.1016\/S0084-3741(09)79335-7"},{"key":"1642_CR19682","doi-asserted-by":"crossref","unstructured":"Badr M, Kyriakidou E, Atkins A, Harrison S. Aggressive denosumab-related jawnecrosis - a case series. Br Dent J 2017; 223: 13-16.","DOI":"10.1038\/sj.bdj.2017.573"},{"key":"1642_CR19684","doi-asserted-by":"crossref","unstructured":"Cassoni A, Romeo U, Terenzi V et al. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? Case Rep Dent 2016; DOI: 10.1155\/2016\/2856926.","DOI":"10.1155\/2016\/2856926"},{"key":"1642_CR19686","doi-asserted-by":"crossref","unstructured":"Preidl R H M, Ebker T, Raithel M, Wehrhan F, Neukam F W, Stockmann P. Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report. BMC Gastroenterol 2014; 14: 1-6.","DOI":"10.1186\/1471-230X-14-6"},{"key":"1642_CR19688","doi-asserted-by":"crossref","unstructured":"Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005; 4: 637-641.","DOI":"10.1517\/14740338.4.4.637"},{"key":"1642_CR19691","doi-asserted-by":"crossref","unstructured":"Lawrance I C, Radford-Smith G L, Bampton P A et al. Serious infections in patients with inflammatory bowel disease receiving antitumournecrosisfactoralpha therapy: An Australian and New Zealand experience. J Gastroenterol Hepatolo 2010; 25: 1732-1738.","DOI":"10.1111\/j.1440-1746.2010.06407.x"},{"key":"1642_CR19693","doi-asserted-by":"crossref","unstructured":"Ebker T, Rech J, von Wilmowsky C, Neukam F W, Stockmann P. Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology (Oxford) 2013; 52: 218-220.","DOI":"10.1093\/rheumatology\/kes351"},{"key":"1642_CR19695","doi-asserted-by":"crossref","unstructured":"Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110: 463-469.","DOI":"10.1016\/j.tripleo.2010.04.049"},{"key":"1642_CR19698","doi-asserted-by":"crossref","unstructured":"Melloni C, Tuttolomondo A, Anfosso A, Calamia C, Clemente F D, Cordova A. Sunitinib related osteonecrosis of the jaw (SURONJ): a rare occurrence? Eur J Plast Surg 2016; 39: 161-162.","DOI":"10.1007\/s00238-015-1112-3"},{"key":"1642_CR19700","doi-asserted-by":"crossref","unstructured":"Guillet M, Walter T, Scoazec J Y, Vial T, Lombard-Bohas C, Dumortier J. Sorafenib-Induced Bilateral Osteonecrosis of Femoral Heads. J Clin Onco 2010; DOI: 10.1200\/JCO.2009.23.4252.","DOI":"10.1200\/JCO.2009.23.4252"},{"key":"1642_CR19703","doi-asserted-by":"crossref","unstructured":"Guarneri V, Miles D, Robert N, Di\u00e9ras V, Glaspy J, Smith I. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181-188.","DOI":"10.1007\/s10549-010-0866-3"},{"key":"1642_CR19705","doi-asserted-by":"crossref","unstructured":"Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky M S. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. J Oral Maxillofac Surg 2013; 17: 303-306.","DOI":"10.1007\/s10006-012-0379-9"},{"key":"1642_CR19708","doi-asserted-by":"crossref","unstructured":"Lescaille G, Coudert A E, Baaroun V et al. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. Bone 2014; 58: 103-107.","DOI":"10.1016\/j.bone.2013.10.002"},{"key":"1642_CR19710","doi-asserted-by":"crossref","unstructured":"Allegra A, Oteri G, Alonci A et al. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg 2014; 42: 279-282.","DOI":"10.1016\/j.jcms.2013.05.014"},{"key":"1642_CR19712","doi-asserted-by":"crossref","unstructured":"Subramanian G, Quek S Y P. Comment on Narv\u00e1ez et al.: Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw. Osteoporosis Int 2013; 24: 735-736.","DOI":"10.1007\/s00198-012-1995-9"},{"key":"1642_CR19715","doi-asserted-by":"crossref","unstructured":"Weigert K L, Lewgoy J, Mazzoleni D S, Franco F R, Enriconi L, Sasso J H. Rituximab and Osteonecrosis of The Jaws: Case Study. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; DOI: 10.1016\/j.oooo.2013.12.203.","DOI":"10.1016\/j.oooo.2013.12.203"},{"key":"1642_CR19717","doi-asserted-by":"crossref","unstructured":"Bagan J V, Bagan L, Poveda R, Scully C. Mitoxantrone as a contributing factor in medication-related osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2016; 45: 377-379.","DOI":"10.1016\/j.ijom.2015.09.025"},{"key":"1642_CR19719","doi-asserted-by":"crossref","unstructured":"Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) among general dental practitioners. Br Dent J 2017; 222: 121-125.","DOI":"10.1038\/sj.bdj.2017.79"},{"key":"1642_CR19721","unstructured":"Lau J, Ng L, Siddiqi A, Zafar S. Paediatric Dentists Treating Children on Bisphosphonates: A Cross-Sectional Questionnaire-Based Study. Ped Dent 2019; 41: 3-8."},{"key":"1642_CR19724","unstructured":"Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw. 2017. Available online at http:\/\/www.sdcep.org.uk\/published-guidance\/medication-related-osteonecrosis-of-the-jaw\/ (accessed May 2020)."}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41415-020-1642-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41415-020-1642-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41415-020-1642-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:31Z","timestamp":1684618891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-020-1642-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1038\/s41415-020-1642-3","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"12 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}